Last reviewed · How we verify
OPC-1085EL ophthalmic solution
OPC-1085EL ophthalmic solution is an anti-inflammatory agent.
OPC-1085EL ophthalmic solution is an anti-inflammatory agent. Used for Treatment of dry eye disease.
At a glance
| Generic name | OPC-1085EL ophthalmic solution |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Drug class | anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the production of pro-inflammatory cytokines, thereby reducing inflammation in the eye. This is achieved through its mechanism of action, which is not fully elucidated.
Approved indications
- Treatment of dry eye disease
Common side effects
- Eye irritation
Key clinical trials
- OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects (PHASE3)
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension (PHASE3)
- Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension (PHASE3)
- Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPC-1085EL ophthalmic solution CI brief — competitive landscape report
- OPC-1085EL ophthalmic solution updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI